In-depth trading ideas

Discover detailed market analysis from traders. See how others approach this instrument, compare different strategies, and discover perspectives that can shape your own view.

DBV Technologies (DBVT) — Non-Invasive Food Allergy Breakthrough Company Overview DBV Technologies NASDAQ:DBVT is a clinical-stage biotech developing epicutaneous immunotherapy (EPIT) via the Viaskin® patch for food allergies—an easy, non-invasive approach for pediatrics. Key Catalysts Phase 3 Win (VITESSE): VIASKIN Peanut achieved 46.6% response vs. 14.8% placebo in children 4–7, validating efficacy and safety ahead of a planned BLA in H1 2026. Regulatory & Funding Momentum: Warrant exercises bolster cash; plans to expand into younger age groups increase addressable market. Durability & Platform Potential: Long-term extension data support sustained benefit and optionality across multiple food allergies. Why It Matters Non-invasive, patch-based therapy = high caregiver/child acceptance Clear regulatory path plus broader age expansion → larger, earlier TAM Platform line-of-sight beyond peanut to multi-allergen pipeline Investment Outlook Bullish above: $14.50–$15.00 Target: $28–$30 — supported by Phase 3 efficacy, upcoming BLA, and platform durability. #DBVT #Viaskin #EPIT #FoodAllergy #Pediatrics #Biotech

by Richtv_official

DBV Technologies | Chart & Forecast Summary Key Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Notes On Session # DBV Technologies - Double Formation * A+ Set Up | Wedge Structure Template | Subdivision 1 * (3) Wave Short End - Triple Formation * Neckline | Left & right At 0.90 |Subdivision 2 * Retracement 1 | 50% At 1.15 * Retracement 2 | Short Set Up Alignment | Subdivision 3 Active Sessions On Relevant Range & Elemented Probabilities; London(Upwards) - NYC(Downwards) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Sell

by UnknownUnicorn87383881

DBV Technologies SA On the above bi-weekly chart price action has corrected over 95% since the sell signal (not shown). Now is an excellent long moment. Why? 1) A strong buy signal (not shown). 2) Price action is printing strong bullish divergence, look left. 3) No stock splits. Is it possible price action falls further? Sure. Is it probable? No. Ww Type: investment Risk: <=6% of portfolio Timeframe: Don’t know. Return: Don’t know Stop loss: <= 96 cents

by without_worries

DBVT - Waiting for WEEKLY diversion looking good for DBVP - i set alert on 1W LONG DIV at this point - SET BUY @ 4$

DBV Technologies rally on Positive FDA Communication DBV Technologies Spikes on Positive FDA Communication DBV Technologies received positive responses from the U.S. Food and Drug Administration regarding its application for a peanut allergy treatment. The U.S. FDA provided type A meeting requests to the questions the French company submitted in October following its receipt of a complete response letter in connection with its biologics license application (BLA) for Viaskin Peanut DBV712, its once-daily epicutaneous patch to treat peanut allergy in children ages four to 11. "We are very encouraged by the positive feedback received from the FDA, and we appreciate the clarity provided," said Daniel Tassé, CEO of DBV Technologies. “We look forward to working with our investigators, clinical trial sites, and key stakeholders as we continue in our development of investigational Viaskin Peanut." DBV says it will address details about a new human factor validation study and additional chemistry, manufacturing and controls data in subsequent communication with the FDA. "We intend to advance a remediation plan for Viaskin Peanut and work closely with FDA to review protocols and re-file our BLA as soon as possible, so that we can bring Viaskin Peanut, if approved, to patients suffering from peanut allergies," Tassé said. www.thestreet.com finance.yahoo.com

DBV Technologies Reports H1-20 DBV Technologies Reports H1-20 themarketsignal.com DBV TECHNOLOGIES ADR (NASDAQ:DBVT) is reflecting bullish signals with a RSI of 19.89. The clinical-stage biopharmaceutical company reported financial figures for the H1-20. DBVT reported €225.9 million cash and cash equivalents at the end of H1-20. This compares with €172.0 million in the previous half year ending December 31, 2019, reflecting €53.8 million increase. The company used €79.4 million cash in operating activities, while €1.3 million was generated from investment activities. DBVT reported €7.6 million operating income in H1-20 as against €7.1 million in H1-19. This income generation is attributed to income recognized from Research Tax Credit of the Company. During the first half of this year, the company reported €86.5 million net loss, as against €79.8 million in H1-19.

by Sector_Reports

DBV Technologies Reports H1-20 DBV Technologies Reports H1-20 themarketsignal.com DBV TECHNOLOGIES ADR (NASDAQ:DBVT) is reflecting bullish signals with a RSI of 19.89. The clinical-stage biopharmaceutical company reported financial figures for the H1-20. DBVT reported €225.9 million cash and cash equivalents at the end of H1-20. This compares with €172.0 million in the previous half year ending December 31, 2019, reflecting €53.8 million increase. The company used €79.4 million cash in operating activities, while €1.3 million was generated from investment activities. DBVT reported €7.6 million operating income in H1-20 as against €7.1 million in H1-19. This income generation is attributed to income recognized from Research Tax Credit of the Company. During the first half of this year, the company reported €86.5 million net loss, as against €79.8 million in H1-19.

by Sector_Reports

$DBVT Bio Pharm Company is on our watchlist.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

DBVT - Fallen angle pattern long from current price up to $31.62 DBVT is forming a nice fallen angel formation. It had a nice rally & now pulled back to moving average. We think it will continue upward from here. * Trade Criteria * Date First Found- November 21, 2017 Pattern/Why- Fallen angel Entry Target Criteria- Present price ($24.43) Exit Target Criteria- 1st Target $27.83, 2nd Target $31.62 Stop Loss Criteria- $22.58 Please check back for Trade updates. (Note: Trade update is little delayed here.)

by AcornWealthCorp